On this page
Nystatin and Triamcinolone Acetonide
Overview
Active ingredients
Source: NDC DirectoryForms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
| Polyene Antifungal [EPC] | EPC | All 12 members |
| Polyenes [CS] | CS | All 13 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 207741-001 | NYSTATIN AND TRIAMCINOLONE ACETONIDE | OINTMENT | NYSTATIN; TRIAMCINOLONE ACETONIDE | Prescription | AT |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Original application | 1 | Approved | January 31, 2017 | Standard |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20251022). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Nystatin and Triamcinolone Acetonide Ointment, USP is indicated for the treatment of cutaneous candidiasis; it has been demonstrated that the nystatin-steroid combination provides greater benefit than the nystatin component alone during the first few days of treatment.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION A thin film of Nystatin and Triamcinolone Acetonide Ointment, USP is usually applied to the affected areas twice daily in the morning and evening. The preparation should be discontinued if symptoms persist after 25 days of therapy (see PRECAUTIONS, Laboratory Tests ). Nystatin and Triamcinolone Acetonide Ointment, USP should not be used with occlusive dressings.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS These preparations are contraindicated in those patients with a history of hypersensitivity to any of their components.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS: A single case (approximately one percent of patients studied) of acneiform eruption occurred with use of combined nystatin and triamcinolone acetonide in clinical studies. Nystatin is virtually nontoxic and nonsensitizing and is well tolerated by all age groups, even during prolonged use. Rarely, irritation may occur. The following local adverse reactions are reported infrequently with topical corticosteroids (reactions are listed in an approximate decreasing order of occurrence): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, perioral secondary infection, skin atrophy, striae and miliaria. To report SUSPECTED ADVERSE REACTIONS, contact Padagis ® at 1-866-634-9120 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Description
openFDA Drug LabelingDESCRIPTION Nystatin and Triamcinolone Acetonide Ointment USP for dermatologic use contains the antifungal agent nystatin, USP and the synthetic corticosteroid triamcinolone acetonide, USP. Nystatin, USP is a polyene antimycotic obtained from Streptomyces noursei . It is a yellow to light tan powder, having an odor suggestive of cereals. Is hygroscopic, and is affected by long exposure to light, heat, and air. It freely soluble in dimethylformamide and in dimethyl sulfoxide, slightly to sparingly soluble in methanol, in n-propyl alcohol, and in n-butyl alcohol, practically insoluble in water and in alcohol; insoluble in chloroform and in ether. Structural formula: C 47 H 75 NO 17 MW = 926.11 g/mol Triamcinolone acetonide, USP is designated chemically as Pregna-1, 4-diene-3,20-dione,9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(11β,16α)-9-Fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone. The white to cream colored, crystalline powder, having not more than a slight odor, is practically insoluble in water, sparingly soluble in dehydrated alcohol, in chloroform and in methanol. Structural formula: C 24 H 31 FO 6 MW = 434.50 g/mol Each gram of Nystatin and Triamcinolone Acetonide Ointment provides 100,000 USP Nystatin units and 1 mg Triamcinolone Acetonide, USP in an ointment base of mineral oil and white petrolatum. nystatin-image triamcinolone-structure
Overdosage
openFDA Drug LabelingOVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS , General ); however, acute overdosage and serious adverse effects with dermatologic use are unlikely.
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Nystatin and Triamcinolone Acetonide Ointment, USP is supplied in 15g (NDC 21922-031-04), 30g (NDC 21922-031-05) and 60g (NDC 21922-031-07) tubes. STORAGE Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. Avoid freezing. To report SUSPECTED ADVERSE REACTIONS, contact Encube Ethicals Private Limited at 1-844-369-4671 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Rx only Manufactured by: Encube Ethicals Pvt. Ltd. Plot No. C-1, Madkaim Industrial Estate, Madkaim, Post: Mardol, Ponda, Goa - 403 404, India. Distributed by: Encube Ethicals, Inc. 200 Meredith Drive, Suite 202, Durham, NC 27713, USA Rev 01 November 2022
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: TRIAMCINOLONE ACETONIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 62332-585-15 | 62332-585 | Alembic Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (62332-585-15) / 15 g in 1 TUBE | March 15, 2022 |
| 62332-585-30 | 62332-585 | Alembic Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (62332-585-30) / 30 g in 1 TUBE | March 15, 2022 |
| 62332-585-60 | 62332-585 | Alembic Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (62332-585-60) / 60 g in 1 TUBE | March 15, 2022 |
| 63629-2495-1 | 63629-2495 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (63629-2495-1) / 60 g in 1 TUBE | September 28, 2019 |
| 63629-2496-1 | 63629-2496 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (63629-2496-1) / 30 g in 1 TUBE | September 28, 2019 |
| 63629-2497-1 | 63629-2497 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (63629-2497-1) / 15 g in 1 TUBE | September 28, 2019 |
| 71335-2847-1 | 71335-2847 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (71335-2847-1) / 15 g in 1 TUBE | October 22, 2025 |
| 71335-2857-1 | 71335-2857 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (71335-2857-1) / 30 g in 1 TUBE | October 22, 2025 |
| 72162-1275-2 | 72162-1275 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-1275-2) / 15 g in 1 TUBE | September 26, 2023 |
| 72162-1275-3 | 72162-1275 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-1275-3) / 30 g in 1 TUBE | September 26, 2023 |
| 72162-1275-6 | 72162-1275 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-1275-6) / 60 g in 1 TUBE | September 26, 2023 |
| 72162-1403-2 | 72162-1403 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-1403-2) / 15 g in 1 TUBE | June 18, 2024 |
| 72162-1403-3 | 72162-1403 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-1403-3) / 30 g in 1 TUBE | June 18, 2024 |
| 72162-1403-6 | 72162-1403 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-1403-6) / 60 g in 1 TUBE | June 18, 2024 |
| 21922-031-04 | 21922-031 | Encube Ethicals, Inc. | 1 TUBE in 1 CARTON (21922-031-04) / 15 g in 1 TUBE | September 28, 2019 |
| 21922-031-05 | 21922-031 | Encube Ethicals, Inc. | 1 TUBE in 1 CARTON (21922-031-05) / 30 g in 1 TUBE | September 28, 2019 |
| 21922-031-07 | 21922-031 | Encube Ethicals, Inc. | 1 TUBE in 1 CARTON (21922-031-07) / 60 g in 1 TUBE | September 28, 2019 |
| 68462-799-17 | 68462-799 | Glenmark Pharmaceuticals Inc., USA | 1 TUBE in 1 CARTON (68462-799-17) / 15 g in 1 TUBE | June 23, 2016 |
| 68462-799-35 | 68462-799 | Glenmark Pharmaceuticals Inc., USA | 1 TUBE in 1 CARTON (68462-799-35) / 30 g in 1 TUBE | June 23, 2016 |
| 68462-799-65 | 68462-799 | Glenmark Pharmaceuticals Inc., USA | 1 TUBE in 1 CARTON (68462-799-65) / 60 g in 1 TUBE | June 23, 2016 |
| 33342-483-15 | 33342-483 | Macleods Pharmaceuticals Limited | 1 TUBE in 1 CARTON (33342-483-15) / 15 g in 1 TUBE | September 1, 2021 |
| 33342-483-30 | 33342-483 | Macleods Pharmaceuticals Limited | 1 TUBE in 1 CARTON (33342-483-30) / 30 g in 1 TUBE | September 1, 2021 |
| 33342-483-60 | 33342-483 | Macleods Pharmaceuticals Limited | 1 TUBE in 1 CARTON (33342-483-60) / 60 g in 1 TUBE | September 1, 2021 |
| 45802-244-14 | 45802-244 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-244-14) / 15 g in 1 TUBE | October 18, 2017 |
| 45802-244-94 | 45802-244 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-244-94) / 30 g in 1 TUBE | October 18, 2017 |
| 45802-244-96 | 45802-244 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-244-96) / 60 g in 1 TUBE | October 18, 2017 |
| 51672-1272-1 | 51672-1272 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1272-1) / 15 g in 1 TUBE | March 29, 1993 |
| 51672-1272-2 | 51672-1272 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1272-2) / 30 g in 1 TUBE | March 29, 1993 |
| 51672-1272-3 | 51672-1272 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1272-3) / 60 g in 1 TUBE | March 29, 1993 |
| 72578-088-01 | 72578-088 | Viona Pharmaceuticals Inc | 1 TUBE in 1 CARTON (72578-088-01) / 15 g in 1 TUBE | June 24, 2020 |
| 72578-088-02 | 72578-088 | Viona Pharmaceuticals Inc | 1 TUBE in 1 CARTON (72578-088-02) / 60 g in 1 TUBE | June 24, 2020 |
| 72578-088-04 | 72578-088 | Viona Pharmaceuticals Inc | 1 TUBE in 1 CARTON (72578-088-04) / 30 g in 1 TUBE | June 24, 2020 |
| 70771-1447-1 | 70771-1447 | Zydus Lifesciences Limited | 1 TUBE in 1 CARTON (70771-1447-1) / 15 g in 1 TUBE | November 20, 2018 |
| 70771-1447-2 | 70771-1447 | Zydus Lifesciences Limited | 1 TUBE in 1 CARTON (70771-1447-2) / 30 g in 1 TUBE | November 20, 2018 |
| 70771-1447-3 | 70771-1447 | Zydus Lifesciences Limited | 1 TUBE in 1 CARTON (70771-1447-3) / 60 g in 1 TUBE | November 20, 2018 |
| 62332-585 | 62332-585 | Alembic Pharmaceuticals Inc. | — | March 15, 2022 |
| 63629-2495 | 63629-2495 | Bryant Ranch Prepack | — | September 28, 2019 |
| 63629-2496 | 63629-2496 | Bryant Ranch Prepack | — | September 28, 2019 |
| 63629-2497 | 63629-2497 | Bryant Ranch Prepack | — | September 28, 2019 |
| 71335-2847 | 71335-2847 | Bryant Ranch Prepack | — | September 28, 2019 |
| 71335-2857 | 71335-2857 | Bryant Ranch Prepack | — | September 28, 2019 |
| 72162-1275 | 72162-1275 | Bryant Ranch Prepack | — | September 28, 2019 |
| 72162-1403 | 72162-1403 | Bryant Ranch Prepack | — | October 18, 2017 |
| 21922-031 | 21922-031 | Encube Ethicals, Inc. | — | September 28, 2019 |
| 68462-799 | 68462-799 | Glenmark Pharmaceuticals Inc., USA | — | June 23, 2016 |
| 33342-483 | 33342-483 | Macleods Pharmaceuticals Limited | — | September 1, 2021 |
| 45802-244 | 45802-244 | Padagis Israel Pharmaceuticals Ltd | — | October 18, 2017 |
| 51672-1272 | 51672-1272 | Sun Pharmaceutical Industries, Inc. | — | March 29, 1993 |
| 72578-088 | 72578-088 | Viona Pharmaceuticals Inc | — | June 24, 2020 |
| 70771-1447 | 70771-1447 | Zydus Lifesciences Limited | — | November 20, 2018 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.